Retail Investor 360 is an innovative platform, championing the mission to become the premier digital publisher, to empower readers with related news, intelligence, education, and proprietary research. We feature 360 coverage with the emphasis on biotechnology, investing, and medicine. We seek to ...
more Retail Investor 360 is an innovative platform, championing the mission to become the premier digital publisher, to empower readers with related news, intelligence, education, and proprietary research. We feature 360 coverage with the emphasis on biotechnology, investing, and medicine. We seek to accomplish our mission while strictly adhering to the principles of integrity, ingenuity, humility, and diligence. Vincata Enterprises LLC has full ownerships in our site. We believe that physicians who are rigidly scientific tend to lack the financial analysis prowess of the WS experts. Conversely, WS financial experts usually do not possess a physician's medical expertise. Likewise, PhDs as a group are skillful in data analysis. Nevertheless, they might not be familiar with physicians' prescribing patterns or certain marketing factors forecasting a developing drug's success. Therefore, we believe that these experts would be greatly improve their analytical accuracy if they could leverage one another's complimentary skills. 360's authors are hybrids taking the middle-ground reflective of the integrated approach. Our expertise span beyond financial analysis and valuations. Our authors are experts who possess analytical prowess in trial data, as well as, statistical analysis. Hence, this enabled us an edge in analyzing the biopharmaceutical industry. In order to gain exceptionally accurate analysis and foresight, we employ both data, as well as, field research. Our site is relatively new and we are undergoing many changes. We welcome your feedbacks via email or phone to improve our site's users experience. Moreover, we do not own copyright information pertaining to our news coverage. Please contact us if you do not wish to have any materials removed on our news section.
less
Latest Comments
Corporate Development: USEC, Inc. To Emerge From Bankruptcy Protection On September 30
MannKind Corporation: Jefferies Votes Confidence In Afrezza And Vincata Raises MannKind's PO To $54
MannKind Corporation: Jefferies Votes Confidence In Afrezza And Vincata Raises MannKind's PO To $54
MannKind Corporation: Why Lantus And Afrezza Do Not Cause Cancer
MannKind Corporation: Why Lantus And Afrezza Do Not Cause Cancer
MannKind Corporation: Why Lantus And Afrezza Do Not Cause Cancer
MannKind Corporation: Why Lantus And Afrezza Do Not Cause Cancer